By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
Fresenius Kabi, a global healthcare company that has been in China for approximately 40 years, ranks among the top 10 non-Chinese pharmaceutical firms in the country, according to President and CEO Pierluigi Antonelli.
Antonelli said China is one of the company's top three global markets, alongside its operations in over 100 countries. He emphasized the enduring appeal of the Chinese market and noted its significant growth potential. He said that healthcare spending in China was around 1.3 trillion euros in 2022 (about $1.4 trillion) and is projected to rise to 2.4 trillion euros (about $2.6 trillion) U.S. by 2030.
Adding that he has visited China three times in the past 16 months, Antonelli said he is impressed by the country's clear development strategy and rapid progress and expressed confidence in Fresenius Kabi's continued presence in China.